Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.
US biosimilars specialist Coherus BioSciences and China’s Innovent Biologics have struck a deal that gives Coherus US and Canadian rights to a biosimilar version of Avastin (bevacizumab) as well as a “non-exclusive option” to sell Innovent’s biosimilar rival to Rituxan (rituximab) in the US and Canada.
Coherus said it would pay “up to $45m in milestones, including the upfront” for the bevacizumab biosimilar, with milestone payments...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
